{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:01:00Z","timestamp":1774558860511,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>To determine whether topical tobramycin 0.3%\/dexamethasone 0.1% plus ozonized oil eye drops reduces clinical signs and infectious viral titers of presumed viral conjunctivitis more than tobramycin\/dexamethasone eye drops alone.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Prospective, single-blind, randomized, parallel-groups trial. Eighty patients with a clinical diagnosis of presumed viral conjunctivitis were randomizedly divided into two treatment groups: a study group and a control group, 40 for each group. Patients in the study group received topical tobramycin 0.3%\/dexamethasone 0.1% eye drops, plus ozonized oil eye drops, both four times daily; patients in the control group received only topical tobramycin 0.3%\/dexamethasone eye drops four times daily. The treatment was for seven days in both groups. Swabs were taken from the conjunctival fornix for adenovirus PCR analysis on the day of recruitment and at seven days follow-up. Clinical signs were also recorded on the day of recruitment and at follow-up examination: the main outcomes were conjunctival injection and conjunctival chemosis, graded on a 4-point clinical scale, presence or absence of superficial punctate keratitis and subepithelial corneal infiltrates.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>No statistically significant difference was reached in adenoviral infection negativization between the two groups, although the study group showed a higher number of PCR negative results at seven days follow-up. PCR real time detected adenoviral infection in 17 of 24 patients on the day of recruitment and it was positive in 4 patients on the seventh day (viral positivity reduction of 76%). In the control group PCR was positive for adenovirus in 18 of 24 patients on the day of recruitment and in 7 patients at seven days follow-up (reduction of 61%). There was statistically significant difference on conjunctival clinical signs between the study and control groups. Significant difference was also found on superficial punctate keratitis resolution between the study and the control group. In the former superficial punctate keratitis was detected in 14 eyes on the first day and in 5 eyes after seven days while in the latter superficial punctate keratitis was found in 124 eyes on the first day and in 6 eyes on the seventh day. No difference was found in subepithelial corneal infiltrates appearance between the two groups.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The use of ozonized-oil containing eye drops in combination with topical tobramycin 0.3%\/dexamethasone 0.1% eye drops four times daily seems to reduce the signs of conjunctivitis, and the duration of viral infection, although it does not affect the subepithelial corneal infiltrates appearance.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10792-020-01503-4","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T06:54:52Z","timestamp":1595400892000},"page":"3209-3215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The role of ozonized oil and a combination of tobramycin\/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3812-9219","authenticated-orcid":false,"given":"C.","family":"Cagini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mariniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Muzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Balducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Levorato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mencacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"issue":"16","key":"1503_CR1","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jama.2013.280318","volume":"310","author":"AA Azari","year":"2013","unstructured":"Azari AA, Barney NP (2013) Conjunctivitis: a systematic review of diagnosis and treatment. JAMA 310(16):1721\u20131729","journal-title":"JAMA"},{"key":"1503_CR2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/oxfordjournals.epirev.a036304","volume":"9","author":"E Ford","year":"1987","unstructured":"Ford E, Nelson KE, Warren D (1987) Epidemiology of epidemic keratoconjunctivitis. Epidemiol Rev 9:244\u2013261","journal-title":"Epidemiol Rev"},{"key":"1503_CR3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0161-6420(02)00992-2","volume":"109","author":"J Hillenkamp","year":"2002","unstructured":"Hillenkamp J, Reinhard T, Ross RS, B\u00f6hringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehardt E, Sundmacher R (2002) The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 109:845\u2013850","journal-title":"Ophthalmology"},{"key":"1503_CR4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.2005.21.157","volume":"21","author":"B Teuchner","year":"2005","unstructured":"Teuchner B, Nagl M, Schidlbauer A, Ishiko H, Dragosits E, Ulmer H, Aoki K, Ohno S, Mizuki N, Gottardi W, Larcher C (2005) Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis\u2014a double-blind, randomized, phase-2 clinical trial. J Ocul Pharmacol Ther 21:157\u2013164","journal-title":"J Ocul Pharmacol Ther"},{"key":"1503_CR5","first-page":"460","volume":"41","author":"EG Romanowski","year":"2000","unstructured":"Romanowski EG, Gordon YJ (2000) Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 41:460\u2013463","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1503_CR6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.survophthal.2015.04.001","volume":"60","author":"V Jhanji","year":"2015","unstructured":"Jhanji V, Chan TC, Li EY, Agarwal K, Vajpayee RB (2015) Adenoviral keratoconjunctivitis. Surv Ophthalmol 60:435\u2013443","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 1","key":"1503_CR7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/ICL.0000000000000226","volume":"44","author":"D Garcia-Zalisnak","year":"2018","unstructured":"Garcia-Zalisnak D, Rapuano C, Sheppard JD, Davis AR (2018) Adenovirus ocular infections: prevalence pathology, pitfalls, and practical pointers. Eye Contact Lens 44(Suppl 1):S1\u2013S7","journal-title":"Eye Contact Lens"},{"issue":"4","key":"1503_CR8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/jcm.15.4.635-639.1982","volume":"15","author":"RL Berkelman","year":"1982","unstructured":"Berkelman RL, Holland BW, Anderson RL (1982) Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol 15(4):635\u2013639","journal-title":"J Clin Microbiol"},{"issue":"1","key":"1503_CR9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9394(14)71640-X","volume":"124","author":"SJ Isenberg","year":"1997","unstructured":"Isenberg SJ, Apt L, Yoshimori R, Pham C, Lam NK (1997) Efficacy of topical povidone-iodine during the first week after ophthalmic surgery. Am J Ophthalmol 124(1):31\u201335","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"1503_CR10","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0886-3350(01)00863-X","volume":"27","author":"N Mohan","year":"2001","unstructured":"Mohan N, Gupta V, Tandon R, Gupta SK, Vajpayee RB (2001) Topical ciprofloxacin-dexamethasone combination therapy after cataract surgery: randomized controlled clinical trial. J Cataract Refract Surg 27(12):1975\u20131978","journal-title":"J Cataract Refract Surg"},{"issue":"12","key":"1503_CR11","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0161-6420(91)32052-9","volume":"98","author":"MG Speaker","year":"1991","unstructured":"Speaker MG, Menikoff JA (1991) Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 98(12):1769\u20131775","journal-title":"Ophthalmology"},{"key":"1503_CR12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archopht.1996.01100130573014","volume":"114","author":"EG Romanowski","year":"1996","unstructured":"Romanowski EG, Roba LA, Wiley L, Araullo-Cruz T, Gordon YJ (1996) The effects of corticosteroids on adenoviral replication. Arch Ophthalmol 114:581\u2013585","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1503_CR13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000488846","volume":"9","author":"L Spadea","year":"2018","unstructured":"Spadea L, Tonti E, Spaterna A, Marchegiani A (2018) Use of ozone-based eye drops: a series of cases in veterinary and human spontaneous ocular pathologies. Case Rep Ophthalmol 9(2):287\u2013298","journal-title":"Case Rep Ophthalmol"},{"issue":"6","key":"1503_CR14","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1365-2133.2005.06939.x","volume":"153","author":"G Valacchi","year":"2005","unstructured":"Valacchi G, Fortino V, Bocci V (2005) The dual action of ozone on the skin. Br J Dermatol 153(6):1096\u20131100","journal-title":"Br J Dermatol"},{"issue":"7","key":"1503_CR15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/02713683.2018.1461907","volume":"43","author":"MSM Mohamed","year":"2018","unstructured":"Mohamed MSM, Abdallah AA, Mahran MH, Shalaby AM (2018) Potential alternative treatment of ocular bacterial infections by oil derived from Syzygium aromaticum flower (Clove). Curr Eye Res 43(7):873\u2013881","journal-title":"Curr Eye Res"},{"key":"1503_CR16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2147\/IDR.S162669","volume":"11","author":"DI Chigbu","year":"2018","unstructured":"Chigbu DI, Labib BA (2018) Pathogenesis and management of adenoviral keratoconjunctivitis. Infect Drug Resist 11:981\u2013993","journal-title":"Infect Drug Resist"},{"key":"1503_CR17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-3476(81)80754-8","volume":"98","author":"F Gigliotti","year":"1981","unstructured":"Gigliotti F, Williams WT, Hayden FG, Hendley JO, Benjamin J, Dickens M, Gleason C, Perriello VA, Wood J (1981) Etiology of acute conjunctivitis in children. J Pediatr 98:531\u2013536","journal-title":"J Pediatr"},{"key":"1503_CR18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ije\/16.1.98","volume":"16","author":"K Ishii","year":"1987","unstructured":"Ishii K, Nakazono N, Fujinaga K, Fujii S, Kato M, Ohtsuka H, Aoki K, Chen CW, Lin CC, Sheu MM, Lin KH, Oum BS, Lee SH, Chun CH, Yoshii T, Yamazaki S (1987) Comparative studies on aetiology and epidemiology of viral conjunctivitis in three countries of East Asia-Japan, Taiwan and South Korea. Int J Epidemiol 16:98\u2013103","journal-title":"Int J Epidemiol"},{"key":"1503_CR19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0035-9203(92)90328-A","volume":"86","author":"RM Woodland","year":"1992","unstructured":"Woodland RM, Darougar S, Thaker U, Cornell L, Siddique M, Wania J, Shah M (1992) Causes of conjunctivitis and keratoconjunctivitis in Karachi, Pakistan. Trans R Soc Trop Med Hyg 86:317\u2013320","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1503_CR20","first-page":"182","volume":"50","author":"G Torres Rojas","year":"1998","unstructured":"Torres Rojas G, Goyenechea A, Savon C, Valdes O, Oropesa I (1998) The incidence of adenoviruses in viral conjunctivitis. Rev Cubana Med Trop 50:182\u2013185","journal-title":"Rev Cubana Med Trop"},{"issue":"3","key":"1503_CR21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archopht.1972.01000020260005","volume":"87","author":"CR Dawson","year":"1972","unstructured":"Dawson CR, Hanna L, Togni B (1972) Adenovirus type 8 infections in the United States IV. Observations on the pathogenesis of lesions in severe eye disease. Arch Ophthalmol 87(3):258\u2013268","journal-title":"Arch Ophthalmol"},{"key":"1503_CR22","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0161-6420(88)32994-5","volume":"95","author":"KJ Hyde","year":"1988","unstructured":"Hyde KJ, Berger ST (1988) Epidemic keratoconjunctivitis and lacrimal excretory system obstruction. Ophthalmology 95:1447\u20131449","journal-title":"Ophthalmology"},{"key":"1503_CR23","first-page":"63","volume":"23","author":"LE Colon","year":"1991","unstructured":"Colon LE (1991) Keratoconjunctivitis due to adenovirus type 8: report on a large outbreak. Ann Ophthalmol 23:63\u201365","journal-title":"Ann Ophthalmol"},{"issue":"8","key":"1503_CR24","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1185\/03007990903038269","volume":"25","author":"TP O\u2019Brien","year":"2009","unstructured":"O\u2019Brien TP, Jeng BH, McDonald M, Raizman MB (2009) Acute conjunctivitis: truth and misconceptions. Curr Med Res Opin 25(8):1953\u20131961","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1503_CR25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0161-6420(93)31389-8","volume":"100","author":"YJ Gordon","year":"1993","unstructured":"Gordon YJ, Gordon RY, Romanowski E, Araullo-Cruz TP (1993) Prolonged recovery of desiccated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces in vitro. Ophthalmology 100(12):1835\u20131839 discussion 1839\u20131840","journal-title":"Ophthalmology"},{"key":"1503_CR26","unstructured":"American Academy of Ophthalmology (2011) Cornea\/External Disease Panel. Preferred Practice Pattern Guidelines: Conjunctivitis-Limited Revision. American Academy of Ophthalmology; San Francisco, CA"},{"issue":"2","key":"1503_CR27","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1111\/aos.14243","volume":"98","author":"A Pinna","year":"2020","unstructured":"Pinna A, Donadu MG, Usai D, Dore S, D'Amico-Ricci G, Boscia F, Zanetti S (2020) In vitro antimicrobial activity of a new ophthalmic solution containing povidone-iodine 0.6% (IODIM\u00ae). Acta Ophthalmol. 98(2):e178\u2013e180","journal-title":"Acta Ophthalmol."},{"issue":"8","key":"1503_CR28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12325-009-0062-1","volume":"26","author":"JS Pelletier","year":"2009","unstructured":"Pelletier JS, Stewart K, Trattler W, Ritterband DC, Braverman S, Samson CM, Liang B, Capriotti JA (2009) A combination povidone-iodine 0.4%\/ dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther 26(8):776\u2013783","journal-title":"Adv Ther"},{"issue":"8","key":"1503_CR29","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1111\/aos.13416","volume":"95","author":"N Kovalyuk","year":"2017","unstructured":"Kovalyuk N, Kaiserman I, Mimouni M, Cohen O, Levartovsky S, Sherbany H, Mandelboim M (2017) Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study. Acta Ophthalmol 95(8):e686\u2013e692","journal-title":"Acta Ophthalmol"},{"key":"1503_CR30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2018.05.012","volume":"194","author":"JS Pepose","year":"2018","unstructured":"Pepose JS, Ahuja A, Liu W, Narvekar A, Haque R (2018) Randomized, controlled, phase 2 trial of povidone-iodine\/dexamethasone ophthalmic suspension for treatment of adenoviral conjunctivitis. Am J Ophthalmol 194:7\u201315","journal-title":"Am J Ophthalmol"},{"key":"1503_CR31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2147\/OPTH.S191275","volume":"13","author":"JS Pepose","year":"2019","unstructured":"Pepose JS, Narvekar A, Liu W, Haque R (2019) A randomized controlled trial of povidone-iodine\/dexamethasone ophthalmic suspension for acute viral conjunctivitis. Clin Ophthalmol 13:535\u2013544","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"1503_CR32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/ICO.0000000000001982","volume":"38","author":"EJ Holland","year":"2019","unstructured":"Holland EJ, Fingeret M, Mah FS (2019) Use of topical steroids in conjunctivitis: a review of the evidence. Cornea 38(8):1062\u20131067","journal-title":"Cornea"},{"key":"1503_CR33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/157489109788490271","volume":"4","author":"V Travagli","year":"2009","unstructured":"Travagli V, Zanardi I, Bocci V (2009) Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims. Recent Pat Anti-Infect Drug Discovery 4:130\u2013142","journal-title":"Recent Pat Anti-Infect Drug Discovery"},{"issue":"3","key":"1503_CR34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3346\/jkms.2009.24.3.368","volume":"24","author":"HS Kim","year":"2009","unstructured":"Kim HS, Noh SU, Han YW, Kim KM, Kang H, Kim HO, Park YM (2009) Therapeutic effects of topical application of ozone on acute cutaneous woundhealing. J Korean Med Sci 24(3):368\u2013374","journal-title":"J Korean Med Sci"},{"issue":"1","key":"1503_CR35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jviromet.2008.06.004","volume":"153","author":"BK Murray","year":"2008","unstructured":"Murray BK, Ohmine S, Tomer DP, Jensen KJ, Johnson FB, Kirsi JJ, Robison RA, O'Neill KL (2008) Virion disruption by ozone-mediated reactive oxygen species. J Virol Methods 153(1):74\u201377","journal-title":"J Virol Methods"},{"key":"1503_CR36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000050884","volume":"215","author":"K Kashiwagi","year":"2001","unstructured":"Kashiwagi K, Saito K, Wang YD, Takahashi H, Ishijima K, Tsukahara S (2001) Safety of ozonated solution as an antiseptic of the ocular surface prior to ophthalmic surgery. Ophthalmologica 215:351\u2013356","journal-title":"Ophthalmologica"},{"key":"1503_CR37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4236\/jbise.2019.127026","volume":"12","author":"A Cutarelli","year":"2019","unstructured":"Cutarelli A, Carlini G, Sarno F, Nebbioso A, Garofalo F, Altucci L, Corrado F (2019) The role of ozone carried by liposomes in the therapy of infectious and skin-regenerating ocular surface. J Biomed Sci Eng 12:347\u2013353","journal-title":"J Biomed Sci Eng"},{"issue":"3","key":"1503_CR38","first-page":"289","volume":"36","author":"M Montevecchi","year":"2013","unstructured":"Montevecchi M, Dorigo A, Cricca M, Checchi L (2013) Comparison of the antibacterial activity of an ozonated oil with chlorhexidine digluconate and povidone-iodine. A disk diffusion test. New Microbiol 36(3):289\u2013302","journal-title":"New Microbiol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01503-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-020-01503-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01503-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T23:16:20Z","timestamp":1626909380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-020-01503-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1007\/s10792-020-01503-4","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}